All In Biotech

Drug Trial Radar · NCT00005823

Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over

Last checked: Nov 19, 2026Latest source record: Dec 18, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,000

Planned (sponsor's estimate)

Start

Dec 1998

Primary completion

Not stated

Study completion Dec 2007

Sponsor

Lead sponsor
Leukemia Research FundAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known if stronger doses of chemotherapy given over a longer period of time are as well tolerated or as effective as less intensive chemotherapy. PURPOSE: This randomized phase III trial is studying intensive regimens of chemotherapy to see how well they work compared to nonintensive regimens of chemotherapy in treating older patients with acute myeloid leukemia or myelodysplastic syndrome.

Conditions

  • Leukemia
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasms

Interventions

  • cytarabineDrug

  • daunorubicin hydrochlorideDrug

  • etoposideDrug

  • hydroxyureaDrug

  • idarubicinDrug

  • mitoxantrone hydrochlorideDrug

  • thioguanineDrug

  • tretinoinDrug

  • valspodarDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Survival
  2. Response achievement
  3. Response duration

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Queen Elizabeth Hospital at University of Birmingham

    Birmingham, England, United Kingdom

  • University College Hospital

    London, England, United Kingdom

  • University Hospital of Wales

    Cardiff, Wales, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.